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Synopsis: Biochemical, hemodynamic or echocardiographic biomarkers should be evaluated, 
as a weak association with peripartum clinical characteristics on postpartum chronic 
hypertension in pre-eclamptic women is only noted   









Objective: To assess the prevalence of postpartum, new-onset chronic hypertension 
following pre-eclampsia and to determine whether maternal, fetal and peripartum 
factors are associated with it.  
Methods: This study was conducted in a tertiary center in south India, between June 
2018 and February 2019, including pre-eclamptic women who completed at least three 
months follow-up as a part of an ongoing cohort.  Demographic, medical and 
laboratory details were collected.  Primary outcome was a diagnosis of new-onset 
chronic hypertension at three months.  
Results: Postpartum chronic hypertension at three months was noted in 32(18.1%) 
women. During postnatal follow-up, two (1.1%) women suffered hemiplegia from 
stroke and 19(10.7%) had elevated serum creatinine levels (>1.1mg/dl) at three 
months. On multivariate analysis, advancing maternal age (aOR=1.10, 95%CI 1.01-
1.21), multiparity (aOR=2.79, 95%CI 1.07-7.24) and eclampsia (aOR=3.07, 95%CI 
1.03-9.13) significantly increased the risk of chronic hypertension at three months 
post-partum.  
Conclusion: One-in-five women present with a diagnosis of new-onset chronic 
hypertension within three months postpartum in a cohort of predominantly preterm 
and/or severe pre-eclampsia. A significant but weak association of chronic 
hypertension with peripartum clinical characteristics was noted. Role of biochemical, 
hemodynamic and echocardiographic biomarkers should be evaluated for prediction 









Pre-eclampsia, a progressive multi-systemic disorder, complicates 3-5% of the 
pregnancies and increases the risk of cardiovascular morbidity/mortality in mothers 
[1]. Recent evidence suggests that the maternal cardiovascular system is not only 
dysfunctional at the time of pre-eclampsia diagnosis, but that it also plays an important 
role in the pathogenesis of the disorder [2,3]. The latter hypothesis is consistent with 
the finding that women whose pregnancies were complicated by pre-eclampsia are at 
increased lifetime risk of chronic hypertension, stroke, myocardial infarction and other 
cardiovascular events [4-7]. The risk of future cardiovascular disease is eight-times 
higher than after normotensive pregnancies, and much higher when pre-eclampsia 
occurred preterm or was associated with fetal growth restriction [4,8]. 
Following pre-eclamptic pregnancy, maternal blood pressure typically normalizes 
within three months postpartum – persistent hypertension beyond this period is an 
indication for referral for further evaluation [9,10]. Even though the postpartum 
maternal cardiovascular legacy of pre-eclampsia is well recognized, it has always 
been presumed that this occurs several years remote to the index pregnancy. 
International Federation of Gynecology and Obstetrics (FIGO) in the postpartum 
initiative on the future risk on maternal health from pregnancy comorbidities suggest 
the lack of evidence regarding the strategies as when and how often to follow up these 
women which would be the most cost-effective at a population level [11]. 
More recent reports suggest that maternal chronic hypertension has suggested that 
the peak incidence may occur much earlier and that the magnitude of the risk is much 
higher [12,13]. Early diagnosis and treatment of chronic hypertension are associated 
with a reduction in the individual risk for developing cardiovascular disease of up to 
50% [14]. This study aimed to assess the prevalence of postpartum, new-onset 
chronic hypertension following pre-eclampsia and to determine whether maternal, fetal 
and peripartum factors can influence this risk.  
MATERIAL AND METHODS 
This study was based on the data of women with pre-eclampsia followed up as a part 
of the on-going cohort study in the Women and Children’s Hospital attached to the 
Jawaharlal Institute of Postgraduate Medical Education & Research, Pondicherry, 






Obstetricians and Gynecologists (ACOG) 2013 criteria [15], referred and admitted 
between June 2018 and February 2019, were recruited before discharge from hospital 
to the primary study with planned follow-up for 12 months. Records of all women who 
were recruited were reviewed for blood pressure at less than 20 weeks and those 
women with chronic hypertension diagnosed at less than 20 weeks or during the pre-
pregnancy period were excluded. The Ethics Committee (Human Studies) approved 
the primary research proposal leading to the work submitted (certificate (JIP/ 
IEC/2013/3/173). Informed consent was obtained from all women before recruitment 
for follow-up in the study. As per the hospital protocol, women with preeclampsia were 
followed up at two weeks and 6 weeks postpartum and then monthly if the blood 
pressure remain elevated. Anti-hypertensives were titrated according to the blood 
pressure values and were monitored in the local primary health centers.  
Maternal demographic details, obstetric/medical history, and pregnancy outcomes 
were collected from the medical records. Details of laboratory investigation at 
diagnosis and need for postpartum anti-hypertensives medication were also collected. 
Calculation of body mass index (kg/m2) was performed using the height and weight 
noted before 15 weeks of pregnancy. Blood pressure at the time of admission to 
hospital, highest blood pressure recording in the antenatal period (highest reading at 
admission or after admission before the onset of labor), intrapartum period (during 
labor and delivery) and at the time of discharge were recorded. 
A trained research assistant measured blood pressure in the upright sitting position 
after at least 5 minutes of rest. The appropriate arm cuff was placed around the left 
upper arm to measure blood pressure. Two reading five minutes apart, in the same 
arm, with a validated automatic oscillometric blood pressure monitor device (OMRON 
HEM-8712, Omron Healthcare Co Ltd, Japan). Women were classified as 
hypertensive if they met the following criteria: systolic blood pressure >140mmHg, 
diastolic blood pressure >90mmHg or requiring anti-hypertensive medication. The 
primary outcome was chronic hypertension defined as the persistence of hypertension 
at 3 months postpartum. [15] 
Statistical Analysis  
Data analysis was done using STAT 13.1 (StataCorp, Texas, USA). The normality of 






as mean ± standard deviation, or as median and range. Association of the continuous 
data with chronic hypertension was assessed using wither Student t-test or Mann 
Whitney test. Categorical data are presented as frequencies and percentages and chi-
square or Fisher exact test was used to assess its association with postpartum chronic 
hypertension. Multivariable logistic regression analysis was done to study the 
association of various risk factors with the persistence of hypertension at 3 months. A 
p-value of < 0.05 was considered significant. 
RESULTS 
One hundred and ninety-one women with pre-eclampsia during the study period  
completed at least three months follow-up and after excluding 14 women with 
preexisting or chronic hypertension 177 women with preeclampsia was included in the 
final analysis.(Figure 1) Maternal demographic and pregnancy characteristics are 
shown in Table 1. The majority of women were nulliparous (n=115, 65.0%) with 
preterm preeclampsia (n=116, 68.6%), mean age of 25.7 years and mean gestation 
at the birth of 34.1 weeks. Eclampsia and hemolysis elevated liver enzymes, and low 
platelet (HELLP) syndrome complicated 39 (22.3%) and 22 (12.6%) pregnancies, 
respectively. At the time of discharge, 103 women were on antihypertensives, with the 
majority of them receiving either labetalol (n=30) and/or amlodipine (n=26). 
Persistence of hypertension at three months was noted in 32 (18.1%) women. Among 
these women 27 needed anti-hypertensives (Tab Amlodipine 2.5mg [n=20] or 5mg 
[n=7] once daily) at three months. During the postnatal period, two (1.1%) women 
suffered from hemiplegia due to stroke, 19 (10.7%) had elevated serum creatinine 
level (>1.1mg/dl) and 41.5% had abnormal urine protein creatinine ratio values (>0.3). 
In bivariate analysis, maternal age, parity, and chronic kidney disease were 
significantly associated with postpartum chronic hypertension (Tables 2 and 3). On 
multivariate analysis after adjusting for other parameters, only advancing maternal age 
(aOR=1.10), multiparity (aOR=2.79) and eclampsia (aOR=3.07) were significantly 
associated with the diagnosis of new-onset, postpartum chronic hypertension (Table 
4).  
DISCUSSION 
This study investigated the postpartum cardiovascular morbidity in a cohort of referred 






high cardiovascular morbidity with approximately one in five women diagnosed with 
new-onset chronic hypertension and two women with stroke-induced hemiplegia 
within three months of delivery. Although maternal age, parity, and eclampsia were 
statistically associated with adverse postpartum cardiovascular outcomes, they were 
poorly predictive for the development of postpartum chronic hypertension. 
After a pregnancy complicated with hypertensive disorders, maternal blood pressure 
typically returns to normal within three months [8-10 ]. Hypertension per se is regarded 
as an important causal factor for cardiovascular and cerebrovascular disease, with 
timely reduction with antihypertensive shown to have a significant reduction in the 
major events regardless of age and class of drug used. Women and healthcare 
workers are usually unaware of the risk of persistent postpartum hypertension and 
subsequent cardiovascular morbidity is high, especially in low to middle-income 
countries [16]. It is typically assumed that the cardiovascular legacy of preeclampsia 
occurs several decades after the index pregnancy. The rate and timing of postpartum 
chronic hypertension in this study were more severe than that reported in the literature 
[16-22]. Variation in prevalence from previous studies may occur because of 
differences in the timing/severity of pre-eclampsia, the presence of co-morbidity and 
the longer-term outcomes available from large epidemiological databases. More 
recently, in a large population-based study from Denmark assessing shorter-term 
outcomes, the risk of hypertension was found to be highest in the first one to two years 
postpartum and that about thirty percent of women developed hypertension within a 
decade of delivery of a pre-eclamptic pregnancy [12] 
Various risk factors were reported in the earlier studies to be associated with the 
development of postpartum chronic hypertension several years to decades later. 
These include maternal age, ethnic origin, body mass index (BMI), 
pregnancy/postpartum blood pressure, HELLP syndrome and delivering a small for 
gestational age baby [16-21]. Hwang et al.[17] noted that pre-pregnancy BMI, history 
of smoking along with early-onset preeclampsia with end-organ dysfunction to be 
associated with progression to a diagnosis of chronic hypertension postpartum. 
Obesity was found to increase the long-term risk of chronic hypertension in a study of 
54,000 women participating in the Nurses’ Health Study II - regardless of a history of 
hypertensive disorders of pregnancy [18]. Only two previous studies investigated 






[16,19]. The authors showed that persistent postpartum hypertension occurred in 21-
27% of women and was associated with maternal age, Afro-Caribbean ethnicity, 
serum creatinine, need for antihypertensive medication at discharge and those with 
severe pre-eclampsia. However, both studies failed to exclude women with pre-
existing chronic hypertension from the analysis, but they did confirm the poor 
predictive ability of these associations. 
There is only limited data available in the literature regarding the immediate 
postpartum development of new-onset chronic hypertension. Hypertension is part of 
a current epidemic of non-communicable disease and is known to be associated with 
an increased long-term risk of severe cardiovascular disease [22]. Furthermore, most 
of the existing data is derived from high-income countries and may not be 
generalizable to low and middle-income populations. The high rate of new-onset 
postpartum hypertension within three months in our cohort suggests that systematic 
screening for cardiovascular in the postpartum period after severe preterm 
preeclampsia in the low to middle-income countries is justified. The study findings also 
support a more immediate and significant impact on maternal postpartum renal 
morbidity with high rates of elevated serum creatinine level and abnormal urine protein 
creatinine ratio values. Consideration should also be given to postpartum maternal 
renal assessment at follow-up visits. 
The current data confirm that routinely collected information on maternal, fetal and 
delivery characteristics may be associated with postpartum cardiovascular outcomes, 
but do not appear to be useful in determining a high-risk sub-population for targeted 
follow-up. As cardiovascular diseases and pre-eclampsia share common 
pathophysiologic/risk factors, the role of maternal biomarkers for dyslipidemia, insulin 
resistance, hypercoagulability, and inflammation may help in the prediction of 
hypertension [23,24]. Maladaptation to the cardiovascular load and changes in 
pregnancy as noted in echocardiographic evaluation is observed as one of the 
pathophysiological processes in pre-eclampsia [13]. In the future, the evaluation of 
these factors as a predictor for the persistence of maternal hypertension into the 
postpartum period needs to be studied. Identifying such women will provide an 
opportunity to initiate preventive measures/modify the risk to reduce the subsequent 






This is a well-defined prospective study that contained high enough rates of preterm 
pre-eclampsia and severe complications such as eclampsia and HELLP syndrome to 
evaluate the contribution of such factors to the development of postpartum new-onset 
chronic hypertension. There is a concern that the observed rate of postpartum chronic 
hypertension in the study may be higher than anticipated for a routine pre-eclampsia 
population because of the high prevalence of preterm and/or severe preeclampsia in 
the referred cohort. However, most large epidemiological studies report similar rates 
of long-term CVD after both preterm and severe preeclampsia compared to milder and 
term disease, making the risk of such bias low [7,25]. The relatively small cohort 
investigated increases the risk that the study overlooked other factors contributing to 
the development of postpartum hypertension. Although this may be the case, any such 
additional factors will inevitably have weaker odds ratios than observed in the study 
and are unlikely to help improve the identification of women with postpartum 
hypertension. 
CONCLUSION 
One out of five women present with new-onset chronic hypertension within three 
months postpartum in a cohort of predominantly preterm and/or severe pre-eclampsia. 
There was a weak association between advancing maternal age, multi-parity, and 
eclampsia with the diagnosis of postpartum chronic hypertension. Future studies 
assessing biochemical, hemodynamic or echocardiographic biomarkers are required 
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Age, years* 25.2 4.9 28.1 5.7 0.004 
Parity** 
       Nulliparous 
       Multiparous 
 
101 (69.7%) 






Body Mass Index, kg/m2* 25.5 3.8 25.9  4.3 0.691 
Co-morbidities** 
       Diabetes Mellitus 
       Chronic Kidney Disease  
 
12 (8.3 %) 
0(0%) 
 





Pulse Rate, at admission, beats per minute* 86.6  11.3 84.7 12.1 0.396 
Blood Pressure at admission, mm Hg* 
       Systolic 
       Diastolic 
 
146.3  21.9 
93.2 13.3 
 
148.2  17.9 




Highest BP value antenatal, mm Hg* 
       Systolic 
       Diastolic 
 
147.0  16.3 
95.8  9.5 
 
149.3  20.1 




Small for gestational age** 58(40.0%) 15(46.8%) 0.479 
Eclampsia** 28 (19.3%) 11 (34.3%) 0.063 
HELLP syndrome** 19 (13.1%) 3 (9.4%) 0.564 
Magnesium sulphate use** 114 (78.6%) 21 (65.6%) 0.204 
*Mean ± Standard deviation 













Highest BP in labour, mm Hg* 
       Systolic 
       Diastolic 
 
133.4  16.2 







Pulse Rate in labour, beats per minute* 91.1  11.1 93.6 10.4 0.833 
Gestation at birth** 34.2  3.7 33.5  4.2 0.376 
Caesarean section** 82 (59.4%) 17(56.7%) 0.781 
Birth weight, grams* 1892.9  712.3 1608.1  808.9 0.065 
Stillbirth** 20 (13.9 %) 6(18.8 %) 0.707 
Pulse Rate at discharge, beats per minute* 85.9  10.7 87.7  7.6 0.432 
BP at discharge, mm Hg* 
       Systolic 
       Diastolic 
 
123.7 16.0 
82.1  8.4 
 
126.0  7.7 




Antihypertensive at 7 days** 80 (56.7 %) 23 (71.9%) 0.081 
*Mean ± Standard deviation 






Table 3 showing multivariate logistic regression assessing association of various risk factors 




95% confidence interval p value 
Age 1.10 1.01, 1.21 0.047 
Parity** 
       Nulliparous 








Highest BP in labour, mm Hg* 
       Systolic 










Eclampsia** 3.07 1.03, 9.13 0.044 
Gestation at birth** 1.02 0.85, 1.22 0.803 
Birth weight, grams* 1.00 0.99, 1.01 0.524 









Table S1: Comparison of investigation among women who developed chronic hypertension 






Haemoglobin, gm/dl * 10.5  2.3 10.1  3.9 0.355 
Platelet, lakhs per mm3* 2.06  0.92 2.00 0.90 0.762 
Aspartate Transaminase, IU/L*** 25.0 (4.0-775.0) 30.0(16.0-120.0) 0.723 
Alanine Transaminase, IU/L*** 20.0 (5.0-607.0) 23.0(8.0-130.0) 0.912 
Urea, mg/dl* 18.0 (7.0-86.0) 21.0(7.0-47.0) 0.954 
Creatine, mg/dl* 0.7 (0.4-4.92) 0.7 (0.3-9.1) 0.469 
Total protein, gm/dl* 4.4 2.4 4.9 1.9 0.189 
Albumin, gm/dl* 2.3  1.1 2.6 0.9 0.164 
Urine protein >2+, ** 73 (50.3%) 16 (50.0%) 0.482 
*Mean ± Standard deviation 
** n (%) 

















Figure 1: Study participant flow chart 
Pre-eclamptic women with postpartum follow-up for three months (n=191) 
Chronic hypertension (n=32, 18.1%) Elevated serum creatinine > 1.1mg/dl (n=19, 10.7%)  
or abnormal urine protein creatinine ratio  (ratio > 0.3)(n=49, 27.7%) 
Excluded women with chronic hypertension in pregnancy (n=14) 
Pre-eclamptic women included in final analysis (n=177) 
Pre-eclamptic women in the study period (n=243) 
Pre-eclamptic women in the study period (n=243) 
